Sanofi SA

SNW

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2026

    Employees

    74,846

Stocks News & Analysis

stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.
stocks

Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released

Several gaming shares are trading at a discount to our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,836.6095.80-1.07%
CAC 408,080.7466.09-0.81%
DAX 4025,463.81272.43-1.06%
Dow JONES (US)49,430.82767.35-1.53%
FTSE 10010,452.6898.49-0.93%
HKSE22,841.62453.13-1.95%
NASDAQ24,246.78183.11-0.75%
Nikkei 22559,444.21419.930.71%
NZX 50 Index14,247.2517.04-0.12%
S&P 5007,252.6371.00-0.97%
S&P/ASX 2008,730.4091.40-1.04%
SSE Composite Index3,577.6210.21-0.28%

Market Movers